ASA in Prevention of Ovarian Cancer (STICs and STONEs)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03480776|
Recruitment Status : Active, not recruiting
First Posted : March 29, 2018
Last Update Posted : December 19, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Ovarian Cancer Prevention||Drug: Acetylsalicylic acid Other: Placebo||Phase 2|
The standard or usual treatment for women with a high risk gene mutation, BRCA1 or BRCA2, is to have risk-reducing surgery to remove the fallopian tubes and ovaries (bilateral salpingo-oophorectomy or bilateral salpingectomy inclusive of fimbria) after they have decided not to have more children naturally.
Acetylsalicylic Acid (ASA) is a safe, well tolerated drug taken by mouth. ASA has been available for over 100 years and has been used mainly to relieve fever and pain, but also as an anti-inflammatory medication in order to reduce inflammation (swelling).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||117 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women With BRCA 1/2 Mutations (STICs and STONEs)|
|Actual Study Start Date :||April 6, 2018|
|Estimated Primary Completion Date :||March 31, 2024|
|Estimated Study Completion Date :||December 31, 2024|
|Active Comparator: Acetylsalicylic Acid (ASA)||
Drug: Acetylsalicylic acid
81 mg PO daily or 325 mg PO daily
Other Name: ASA
|Sham Comparator: Placebo||
One tablet PO daily
- Proportion of pre- & malignant lesions found during prophylactic risk reduction surgery using a stratified Cochran-Mantel-Haenszel test [ Time Frame: 5 years ]
- Acceptance of the ASA intervention from the self-report Credibility/Expectancy Questionnaire [ Time Frame: 5 years ]
- Compliance of taking ASA by serum monitoring [ Time Frame: 5 years ]
- Compliance of taking ASA by evaluation of treatment completion rates [ Time Frame: 5 years ]
- Compliance of taking ASA by reasons for early discontinuation of protocol intervention. [ Time Frame: 5 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Gender Based Eligibility:||Yes|
|Accepts Healthy Volunteers:||Yes|
- Previously documented germline BRCA1/2 pathogenic mutation or likely pathogenic variant based on the ACMG 2015 guidelines
- Risk-reducing surgery (bilateral salpingo-oophorectomy or bilateral salpingectomy inclusive of fimbria) scheduled for within 6 months to 2 years after the date of randomization as standard of care, for women who have completed their families
- ECOG performance status 0 or 1
- Age ≥ 18 years old
- Subject is able (i.e. sufficiently literate) and willing to complete the Credibility/Expectancy questionnaire in English or French.
- Subject consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each subject must sign a consent form prior to enrollment in the trial to document their willingness to participate
- Subjects must be accessible for treatment and follow up. Subjects randomized on this trial must be treated and followed at the participating centre.
- In accordance with CCTG policy, protocol treatment is to begin within 2 working days after subject randomization
- Women of childbearing potential must have agreed to use a highly effective contraceptive method for the duration of the study treatment and for 30 days post last dose of study medication
Subjects with history of other malignancies, except:
- adequately treated non-melanoma skin cancer;
- curatively treated in-situ cancer of the cervix;
- previously diagnosed (at any point) breast cancer, treated with curative intent; prior chemotherapy is allowed and the last dose must be ≥ 12 months prior to randomization; endocrine therapy for breast cancer is allowed at any time.
- other solid tumours curatively treated with no evidence of disease for > 5 years.
- Subjects who have been treated with any PARP-inhibitors (e.g. olaparib) at any time.
- Subjects with active bleeding or bleeding diathesis.
- Subjects with active peptic ulcer.
- Subjects with renal, hepatic or congestive heart failure.
- Subjects with concurrent use of anti-coagulants and/or anti-platelet agents.
- Subjects with prior bilateral salpingectomy.
- Subjects with history of chronic daily use of ASA or NSAIDs.
- Subjects with intolerance of ASA including subjects with a history of asthma induced by salicylates or substances with a similar action, notably non-steroidal-anti-inflammatory drugs.
- Ongoing or planned pregnancy.
- Subjects who are breastfeeding.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03480776
|Study Chair:||Amit Oza||Univ. Health Network-OCI/Princess Margaret Hospital, Toronto, ON Canada|
|Study Chair:||Stephanie Lheureux||Univ. Health Network-OCI/Princess Margaret Hospital, Toronto, ON Canada|
|Responsible Party:||Canadian Cancer Trials Group|
|Other Study ID Numbers:||
|First Posted:||March 29, 2018 Key Record Dates|
|Last Update Posted:||December 19, 2022|
|Last Verified:||December 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Genital Diseases, Female
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Genital Neoplasms, Female
Endocrine System Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Anti-Inflammatory Agents, Non-Steroidal
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Fibrin Modulating Agents